JP2018525399A - Cck2r−薬物コンジュゲート - Google Patents
Cck2r−薬物コンジュゲート Download PDFInfo
- Publication number
- JP2018525399A JP2018525399A JP2018507646A JP2018507646A JP2018525399A JP 2018525399 A JP2018525399 A JP 2018525399A JP 2018507646 A JP2018507646 A JP 2018507646A JP 2018507646 A JP2018507646 A JP 2018507646A JP 2018525399 A JP2018525399 A JP 2018525399A
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- cancer
- alkenyl
- alkynyl
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CSCCC(C(N[C@@](CC(O)=O)C(NC(Cc1ccccc1)C(N)=O)=O)=O)NC([C@](Cc1c[n]c2ccccc12)NC(CNC([C@](CCSC)NC([C@](Cc(cc1)ccc1O*)NC([C@](CC(O)=O)NI*)=O)=O)=O)=O)=O Chemical compound CSCCC(C(N[C@@](CC(O)=O)C(NC(Cc1ccccc1)C(N)=O)=O)=O)NC([C@](Cc1c[n]c2ccccc12)NC(CNC([C@](CCSC)NC([C@](Cc(cc1)ccc1O*)NC([C@](CC(O)=O)NI*)=O)=O)=O)=O)=O 0.000 description 8
- YXFVVABEGXRONW-UHFFFAOYSA-N Cc1ccccc1 Chemical compound Cc1ccccc1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/12—1,5-Benzodiazepines; Hydrogenated 1,5-benzodiazepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562205411P | 2015-08-14 | 2015-08-14 | |
| US62/205,411 | 2015-08-14 | ||
| US201562261227P | 2015-11-30 | 2015-11-30 | |
| US62/261,227 | 2015-11-30 | ||
| US201662323287P | 2016-04-15 | 2016-04-15 | |
| US62/323,287 | 2016-04-15 | ||
| PCT/US2016/046292 WO2017030859A1 (en) | 2015-08-14 | 2016-08-10 | Cck2r-drug conjugates |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018525399A true JP2018525399A (ja) | 2018-09-06 |
| JP2018525399A5 JP2018525399A5 (enExample) | 2019-09-05 |
Family
ID=58051970
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018507646A Pending JP2018525399A (ja) | 2015-08-14 | 2016-08-10 | Cck2r−薬物コンジュゲート |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10500286B2 (enExample) |
| EP (1) | EP3334447A4 (enExample) |
| JP (1) | JP2018525399A (enExample) |
| CA (1) | CA2995371A1 (enExample) |
| HK (1) | HK1257229A1 (enExample) |
| WO (1) | WO2017030859A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024537766A (ja) * | 2021-09-28 | 2024-10-16 | パウル・シェラー・インスティトゥート | Cck2-rを標的とする化合物による治療および/またはイメージングに対する癌と診断された患者の応答を予測する方法、ならびに癌を選択的に治療および/またはイメージングする方法に使用する化合物 |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11229708B2 (en) | 2015-12-04 | 2022-01-25 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
| US11793880B2 (en) | 2015-12-04 | 2023-10-24 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
| KR20230158005A (ko) | 2021-03-18 | 2023-11-17 | 씨젠 인크. | 생물학적 활성 화합물의 내재화된 접합체로부터의 선택적 약물 방출 |
| CN120554245A (zh) * | 2025-07-30 | 2025-08-29 | 辽宁众辉生物科技有限公司 | 一种氟吡菌酰胺中间体n-乙酰氧基甲基-2-三氟甲基苯甲酰胺的合成方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013126797A1 (en) * | 2012-02-24 | 2013-08-29 | Purdue Research Foundation | Cholecystokinin b receptor targeting for imaging and therapy |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7776814B2 (en) * | 2002-07-09 | 2010-08-17 | R&D-Biopharmaceuticals Gmbh | Tubulysin conjugates |
| US8431714B2 (en) * | 2007-04-16 | 2013-04-30 | University Of Southern California | Synthesis of drug conjugates via reaction with epoxide-containing linkers |
-
2016
- 2016-08-10 HK HK18116265.4A patent/HK1257229A1/zh unknown
- 2016-08-10 JP JP2018507646A patent/JP2018525399A/ja active Pending
- 2016-08-10 WO PCT/US2016/046292 patent/WO2017030859A1/en not_active Ceased
- 2016-08-10 EP EP16837521.0A patent/EP3334447A4/en not_active Withdrawn
- 2016-08-10 CA CA2995371A patent/CA2995371A1/en not_active Abandoned
- 2016-08-10 US US15/751,633 patent/US10500286B2/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013126797A1 (en) * | 2012-02-24 | 2013-08-29 | Purdue Research Foundation | Cholecystokinin b receptor targeting for imaging and therapy |
Non-Patent Citations (2)
| Title |
|---|
| AMINO ACIDS, vol. 41, no. 5, JPN6020020748, 2011, pages 1049 - 1058, ISSN: 0004562622 * |
| DALTON TRANSACTIONS, vol. 40, no. 23, JPN6020020750, 2011, pages 6144 - 6167, ISSN: 0004562623 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024537766A (ja) * | 2021-09-28 | 2024-10-16 | パウル・シェラー・インスティトゥート | Cck2-rを標的とする化合物による治療および/またはイメージングに対する癌と診断された患者の応答を予測する方法、ならびに癌を選択的に治療および/またはイメージングする方法に使用する化合物 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3334447A4 (en) | 2019-07-24 |
| US20180228909A1 (en) | 2018-08-16 |
| US10500286B2 (en) | 2019-12-10 |
| WO2017030859A1 (en) | 2017-02-23 |
| CA2995371A1 (en) | 2017-02-23 |
| HK1257229A1 (zh) | 2019-10-18 |
| EP3334447A1 (en) | 2018-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7079355B2 (ja) | Psma結合性リガンド-リンカー結合体及び使用方法 | |
| WO2010045598A2 (en) | Psma binding ligand-linker conjugates and methods for using | |
| JP2020502130A (ja) | 線維芽細胞活性化タンパク質(fap)標的イメージングおよび治療 | |
| CN104797247A (zh) | 用于治疗由psma表达细胞引起的疾病的共轭物 | |
| US10500286B2 (en) | CCK2R-drug conjugates | |
| US20180110871A1 (en) | Dual disulfide drug conjugates | |
| JP2011523415A (ja) | 新規な二重標的化抗腫瘍複合体 | |
| US20200289659A1 (en) | Conjugates for treating diseases | |
| JP2021501201A (ja) | ステープルペプチドの細胞内送達のためのポリペプチド接合体 | |
| US20200323991A1 (en) | Pbd conjugates for treating diseases | |
| WO2016089879A1 (en) | Conjugates of garftase inhibitors | |
| US10857234B2 (en) | Carbonic anhydrase IX inhibitor conjugates and uses thereof | |
| CN111225688A (zh) | 靶向碳酸酐酶阳性癌症的基于fbsa的治疗和放射性成像缀合物 | |
| JP7027325B2 (ja) | 炭酸無水酵素ixを標的とする薬剤および方法 | |
| US20160303251A1 (en) | Conjugates of garftase inhibitors | |
| JP2021006550A (ja) | 炎症の治療のための抗葉酸剤結合体 | |
| TW201919682A (zh) | 活化Nrf2路徑的新穎化合物 | |
| JP2020117509A (ja) | 疾患を処置するためのコンジュゲート | |
| HK40031566A (en) | Fbsa-based therapeutic and radioimaging conjugates targeting carbonic anhydrase positive cancers | |
| HK40016572A (en) | Luteinizing hormone-releasing hormone receptor (lhrh-r) conjugates and uses thereof | |
| HK40016572B (en) | Luteinizing hormone-releasing hormone receptor (lhrh-r) conjugates and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190729 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190729 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200616 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200915 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210112 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20210803 |